Introduction {#s1}
============

\"I like to think of the meta-analytic process

as similar to being in a helicopter.

On the ground individual trees

are visible with high resolution.

This resolution diminishes as the helicopter

rises, and its place we begin

to see patterns not visible from the ground\"

                                              Ingram Olkin

Systematic reviews and meta-analyses are being used more extensively by researchers and practitioners, thanks to the appeal of a single piece of literature that is immediately able to summarize diverse data on a specific topic \[[@R01],[@R02]\]. They have been established as the most quoted and read article types, even toppling randomized clinical trials, and thus they are likely to play a progressively even greater role in the future of medicine \[[@R03],[@R04]\]. In addition, they are often published in the most prestigious international peer-reviewed journals, reaching thousands of physicians and researchers worldwide.

As with any other analytical and research tool with a long-standing history (*Table 1*), systematic reviews and meta-analyses, despite their major strengths, are well known for several potential major weaknesses.

![Key milestones in systematic review and meta-analysis development.](hsrp-03-161-g001){#F001}

The aim of this review is to provide a concise but sound framework for the critical reading of systematic reviews and meta-analyses and, summarily, their design and conduct, stemming from our extensive experience with this type of research method (*Figure 1*).

![Publications in PubMed authored in the last few years by our research group concerning meta-analytic topics. Pubmed was searched on 30 March 2010 with the following strategy: \"(biondi-zoccai OR Zoccai) AND (meta-analys\* OR metaanalys\* OR metaregress\* OR \"meta-regression\")\".](hsrp-03-161-g002){#F002}

Definitions {#s3}
===========

A systematic review is a viewpoint focusing on a specific clinical problem, being it therapeutic, diagnostic or prognostic (*Table 2*) \[[@R01],[@R05]\].

![Minimal glossary pertinent to systematic reviews and meta-analyses.](hsrp-03-161-g003){#F003}

The term systematic means that all the steps underlying the reviewing process are explicitly and clearly defined, and may be reproduced independently by other researchers. Thus, a formal set of methods is applied to study search (i.e. to the extensive search of primary/original studies), study selection, study appraisal, data abstraction and, when appropriate, data pooling according to statistical methods. Indeed, the term meta-analysis refers to a statistical method used to combine results from several different primary studies in order to provide more precise and valid results. Thus, not all systematic reviews include a meta-analysis, as not all topics are suitable for sound and robust data pooling. At the same time, meta-analysis can be conducted outside the realm of a systematic review (e.g. in the absence of extensive and thorough literature searches), but in such cases results of the meta-analytic efforts should be best viewed as hypothesis-generating only. This depends mainly on the fact that meta-analysis outside the framework of a systematic review has a major risk of publication bias.

Strenghts {#s5}
=========

Systematic reviews (especially when including meta-analytic pooling of quantitative data) have several unique strengths \[[@R01],[@R05]\]. Specifically, they exploit systematic literature searches enabling the retrieval of the whole body of evidence pertaining to a specific clinical question.

Their standardized methods for search, evaluation and selection of primary studies enable reproducibility and an objective stance. Individual primary studies undergo a thorough evaluation for internal validity, together with the identification of the risk for bias All too often, systematic reviews hold their greater strength precisely in their ability to pinpoint weaknesses and fallacies in apparently sound primary studies \[[@R06]\].

Quantitative synthesis by means of meta-analysis also substantially increases statistical power, and yields narrower confidence intervals for statistical inference. The assessment of the effect of an intervention (exposure or diagnostic test) across different settings and times provides estimates and inferences with much greater external validity. The larger sample sizes often achieved by systematic reviews may even offer ample room for testing post-hoc hypotheses or exploring the effects in selected subgroups \[[@R07]\]. Clinical and statistical variability (i.e. heterogeneity and inconsistency) may be exploited by advanced statistical methods such as meta-regression, possibly offering the opportunity to test novel and hitherto unprecedented hypotheses \[[@R08]\]. Finally, meta-regression methods can be used to perform adjusted indirect comparisons or network meta-analyses \[[@R09]\].

Limitations {#s6}
===========

Drawbacks of systematic reviews and meta-analyses are also substantial, and should never be dismissed \[[@R01]\]. Since the first critique of being "an exercise in mega-silliness" and inappropriately \"mixing apples and oranges\" \[[@R10]\], there has been ongoing debate on the most correct approach to choose when meta-analytic pooling should be pursued (e.g. in case of statistical homogeneity and consistency) and when, conversely, the reviewer should refrain from meta-analysis (e.g. in case of severe statistical heterogeneity \[as testified by p values \<0.10 at χ^2^ test\] or significant statistical inconsistency \[as testified by I^2^ values\>50%\]) \[[@R11]\].

Whereas Canadian authors suggest that systematic reviews and meta-analyses from homogenous randomized controlled trials represent the apex of the evidence-based medicine pyramid (discounting for the role of n of 1 randomized trials) \[[@R12]\], others maintain that very large and simple randomized clinical trials offer several premium features, and should always be preferred, when available, to systematic reviews \[[@R13]\].

It is also all too common to retrieve only a few studies which focus on a given clinical topic, or otherwise studies may be found, but of such low quality, that including or even discussing them in the setting of a systematic review may appear misleading. Indeed, in such cases the meta-analysis itself can be considered misleading. Nonetheless, key insights may be gained in these cases by exploring sources of heterogeneity, stratified analyses, and meta-regressions. This drawback is strictly associated with the major threat to meta-analysis validity called the small study effect (also, albeit inappropriately, called small study bias or publication bias) \[[@R01]\]. Indeed, it is common to recognize, especially in large datasets, that small primary studies are more likely to be reported, published and quoted if their results are significant. Conversely, small non-significant studies often fail to reach publication or dissemination, and may thus be very easily missed, even after thorough literature searches. Combining results from these "biased" small studies with those of larger studies (which are usually published even if negative or non-significant) may inappropriately deviate summary effect estimates away from the true value. Unfortunately, despite the availability of several graphical and analytical tests \[[@R14]\] small study effects (which actually encompass publication bias) are potentially always present in a systematic review and should never be disregarded.

In addition, in the ongoing worldwide research effort, it is all too common for reviewers to focus only on English language studies, and thus unduly restricting their search and excluding potentially important works (e.g. from China or Japan). Another common critique is that systematic reviews and meta-analyses are not original research (*Figure 2*)

![Parallel hierarchy of scientific studies in clinical research. Modified from Biondi-Zoccai et al. (2).](hsrp-03-161-g004){#F004}

The reader is left free to form independently his informed opinion on this specific issue. Nonetheless, the main meter to judge a systematic review should be its novelty and usefulness for the very same reader, not whether it appears as original or secondary research \[[@R02]\].

Finally, a burning issue is whether results from large systematic reviews and meta-analyses can ever be applied to the single individual under our care. This question cannot be answered once and for all, and judgment should always be employed when considering the application of meta-analytic results to a specific patient. Unless proven otherwise by a significant test of interaction, all patients should be considered likely to similarly benefit from a specific treatment or diagnostic strategy \[[@R12]\].

Appraising primary studies, systematic reviews and meta-analyses {#s8}
================================================================

Unfortunately publication of a systematic review in a peer-reviewed journal is not definitive evidence of its internal validity and usefulness for the clinical practitioner or researcher \[[@R15]\]. Peer-review is not very accomplished in judging or improving the quality of scientific reviews, and many examples of bad or unsuccessful peer-reviewing efforts can be easily found. However, just as "democracy is the worst form of government except all those other forms that have been tried" (Sir Winston Churchill), peer-review is the "worst" method used to evaluate scientific research except all other methods that have been tried so far. This applies to all clinical research products in general and so also applies to systematic reviews and meta-analyses. Thus, provided that meta-analyses are accurately and thoroughly reported, the burden of quality appraisal lies largely, as usual, in the eye of the beholder (i.e. the reader).

Assessment of primary research studies as well as systematic reviews and meta-analyses should be based on their internal validity and then, provided it is reasonably adequate, on their results and external validity \[[@R12]\]. Whereas interpretation of results and external validity of any research endeavor depends on the specific context of application, and is thus best left open to the individual judgment of the reader or decision-maker, internal validity can be evaluated in a rather structured and validated way. Recent guidance on the appraisal of the risk of bias in primary research studies within the context of a systematic review has been provided by The Cochrane Collaboration, and includes a separate assessment of the risk of selection, performance, attrition and adjudication bias (*Table 3*) \[[@R16]\]

![A modified version of The Cochrane Collaboration risk of bias assessment tool for the appraisal of primary studies.(16)\*](hsrp-03-161-g005){#F005}

Other valid and complementary approaches, targeted for specific study designs, have been proposed by advocates of evidence-based medicine methods, and include the Jadad score, the Delphi list, and the Megens-Harris list \[[@R12]\]. Nonetheless, even external validity can be formally evaluated by focusing on the population included, the control group, and result interpretation. Finally, established statistical criteria are available to determine whether a given intervention is effective and similar explicit criteria can inform on the presence of clinical significance.

The quality of a systematic review and meta-analysis depends on several factors, in particular the quality of the primary pooled studies.

Nonetheless, reporting quality (e.g. compliance with current guidelines on drafting and reporting of a meta-analysis by the Preferred Reporting Items for Systematic reviews and Meta-Analyses \[PRISMA\] or Meta-analysis Of Observational Studies in Epidemiology \[MOOSE\] statements) should be clearly distinguished by internal validity \[[@R17],[@R18]\]. This can be low even in well reported reviews, whereas it is generally difficult to judge as highly valid a poorly reported systematic review and meta-analysis. The assessment of the internal validity of a review is quite complex and based on several assumptions, including study search and appraisal, methods for data pooling, and approaches to interpretation of study findings.

However, useful guidance was provided by Oxman and Guyatt with their well validated instrument (*Table 4*) \[[@R19]\].

![Oxman and Guyatt index for the appraisal of reviews. (19)\*](hsrp-03-161-g006){#F006}

More recently, other investigators have suggested other tools for the evaluation of systematic reviews, such as the A Measurement Tool to Assess Systematic Reviews (AMSTAR), and the Veritas plot, which await further validation (*Table 5*, *Figure 3*) \[[@R20],[@R21],[@R22]\].

![The AMSTAR tool for the appraisal of systematic reviews. (20-21)\*](hsrp-03-161-g007){#F007}

![Typical diagram used to generate a Veritas plot (panel A) (22).\
Using this tool, a low quality meta-analysis will be represented by a hexagon with a smaller area (panel B), whereas a high quality meta-analysis will be shown as a hexagon with a larger area (panel C).](hsrp-03-161-g008){#F008}

For those busy critical care physicians wishing for a quicker approach to appraise systematic reviews, a simple two-step approach can be proposed. This is a simplification of the evidence-based medicine approach for the evaluation of sources of clinical evidence, but is nonetheless quite helpful \[[@R12]\]. Evidence-based medicine is "the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients" \[[@R12]\]. It must also be stressed that "the practice of evidence-based medicine requires integration of individual clinical expertise and patient references with the best available external clinical evidence from systematic search" \[[@R12]\]. Systematic reviews and meta-analyses, if well conducted and reported, help us in reducing our efforts in looking for, evaluating, and summarizing the evidence.

But the burden of deciding what to do with the evidence obtained for the care of our individual patient remains ours.

Thus, the first step in appraising a systematic review and meta-analysis is to try and find an answer to the question: can I trust it? In other words, is this review internally valid, does it provide a precise and largely unbiased answer to its scientific question? Providing a definitive assessment of the internal validity of a systematic review is not a simple task, but largely depends on the methods employed and reported regarding study search, selection, abstraction, appraisal and, if appropriate, the study pooling. Even if we can conclude that a given meta-analysis is internally valid, we still have to face the second step in its evaluation. This focuses on the external validity of the study. In other words, can I apply the review results to the case I am facing or will shortly face? More basically it answers the question: so what? Decisions on external validity are highly subjective and may change depending on the clinical, historical, logistical, cultural or ethical context of the evaluator. Nonetheless, systematic reviews and meta-analyses can improve our appraisal of the external validity of any given clinical intervention, by suggesting an overall clinical efficacy (or lack of it).

It is clear that the assessment of the internal validity, and even more importantly the external validity, of any research endeavor, is highly subjective, and thus we leave ample room for the reader to enjoy and appraise them on his or her own.

The only issue that is worth being further stressed is that only collective and constructive, but critical post-publication evaluation of scientific studies can put and maintain them into the appropriate context for their correct and practical exploitation by the clinical researcher and the clinical practitioner.

Systematic reviews and meta-analyses: do it yourself {#s12}
====================================================

Even those not strictly committed to conduct a systematic review may obtain further insights into this clinical research method by understanding the key steps involved in the design, conduct and interpretation of a systematic review \[[@R05]\].

Briefly, a systematic review should always stem from a specific clinical question. Even if the experienced reviewer can probably informally guess the answer to this question the goal of the systematic review will be to confirm or disprove such hypothesis in a formal and structured way. With this goal in mind, the review should be designed as prospectively and in as much in detail as possible, to avoid conscious or unconscious manipulations of methods or data (*Figure 4*).

![Typical algorithm for the design and conduct of a systematic review. Modified from Biondi-Zoccai et al. (5).](hsrp-03-161-g009){#F009}

The next steps are very important, and define the boundaries of the reviewing effort. Specifically, the reviewer should spell out the population of interest, the intervention or exposure to be appraised, the comparison(s) or comparator(s), and the outcome(s). The acronym PICO is often used to remember this approach. As an example, we could be interested in conducting a systematic review focusing on a population (P) of diabetics with coronary artery disease undergoing coronary artery bypass grafting, with the intervention (I) of interest being the administration of bivaridudin as anticoagulant, the comparator (C) being unfractioned heparin, and the outcomes (O) defined as in-hospital rates of death, myocardial infarction, stroke, or major bleeding (including bleeding needing repeat surgery).

After such preliminary steps, the actual review begins with a thorough and extensive search, encompassing several databases (not only MEDLINE/PubMed) with the help of library personnel experienced in literature searches, preferably also including conference abstracts and bibliographies of pertinent articles and reviews. When a list of potentially pertinent citations has been retrieved, these should be assessed and included/excluded based on criteria stemming directly from the PICO approach used to define the clinical question. Study appraisal also includes a formal evaluation of study validity and risk of bias of primary studies, whereas data abstraction, generally performed by at least two independent reviewers with divergences resolved after consensus, provides the quantitative data which will eventually be pooled with meta-analysis \[[@R16]\].

Indeed, provided that studies are relatively homogeneous and consistent, meta-analytic methods are employed to combine effect estimates from single studies into a unique summary effect estimate, with corresponding p values and confidence intervals for the effect (*Figure 5*)

![Typical forest plot generated by RevMan from a systematic review with meta-analytic pooling of dichotomous outcomes (df=degrees of freedom; E=expected cases; O=observed cases; OR=odds ratio). The solid oval highlights event counts in one of the groups under comparison, the solid box shows graphically individual and pooled point effect estimates with 95% confidence intervals, the arrowhead indicates the exact pooled point effect estimate with 95% confidence intervals (CI), the arrow shows the p value for effect, and the dashed oval highlights p value for statistical eterogeneity and measure of statistical inconsistency (I2). Modified from Landoni et al. (30).](hsrp-03-161-g010){#F010}

In many cases results may lead reviewers to go back to the original research question and revise their working hypothesis. The last step relies on the interpretation and dissemination (possibly through publication in a peer-reviewed journal) of the results.

More advanced analytical issues {#s15}
===============================

Unless extensively powered low event rates may often be found in primary research studies (e.g. with\>1000 patients enrolled or with selective recruitment of very high-risk subjects). This may lead to null counts in one or more of the groups undergoing comparison in a controlled trial, generating severe computational hurdles. Indeed, most statistical methods used for meta-analytic pooling require that at least one event has occurred in each study group.

When this is not the case in one or more of the groups under comparison, bias may be introduced with the common practice of adding 0.25 or 0.50 to each group without events \[[@R23]\]. On top of this, when no event has occurred in any group, comparisons are more challenging and data from such an underpowered studies cannot be pooled with standard meta-analytic methods, as variance of the effect estimate approaches infinity. Nonetheless, other approaches (e.g. risk difference, continuity correction or Peto method) can still be used in case of total zero event trials.

Even when all groups undergoing comparison in a specific study have one or more events, the risk of biased estimates and alpha error (i.e. the risk of erroneously dismissing a null hypothesis despite it being true) may be present \[[@R01]\].

Indeed, minor differences in populations with few and rare events may provide nominally significant results (e.g. p=0.048) which however appear quite unstable. In such cases, we recommend reliance on the combined use of p values and 95% confidence intervals, or even making use of 99% confidence intervals. In other cases, a useful rule of thumb is to trust only meta-analyses reporting on at least 100 pooled events per group under comparison.

The risk of erroneously accepting a null hypothesis despite it being false (i.e. the beta error) is also common in systematic reviews and meta-analyses, especially when they include few studies with low event counts. This lack of statistical power (defined as 1-beta) is even more common with meta-regression analyses, which are usually underpowered because of few included studies and regression to the mean \[[@R07]\].

Surrogates may provide an important contribution to clinical research design, by increasing statistical power and offering insights in more than one clinical dimension. However, surrogate end-points (e.g. \>25% increase in serum creatinine from baseline values to identify subclinical renal injury) may be less clinically relevant than hard clinical end-points (death or permanent need for hemodialysis) \[[@R12]\].

Usually, only surrogates which have a direct impact on patient well being and are independently associated with hard clinical end-points should be accepted for the design of clinical research studies. In any case, a study reaching significance based on surrogate end-points alone, but missing significance on analysis of hard end-points should be considered as hypothesis-generating or, at best, underpowered.

Small study bias always potentially threatens the results of a systematic review, as this type of confounding applies to all clinical topics and research study designs (*Figure 6*) \[[@R24]\]

![Typical funnel plot generated by RevMan showing small study bias, ie the asymmetric distribution of effect sizes in function of study precision, with selective publication of only positive small sample studies (RR=relative risk; SE=standard error). Modified from Biondi-Zoccai et al. (24).](hsrp-03-161-g011){#F011}

Although this bias may be less significant in more recent and well financed drug or device studies (e.g. fenoldopam), in older or less well funded studies publication bias may profoundly undermine the results of a systematic review.

This has been all too evident in studies examining the role of acetylcysteine for the prevention of contrast-associated nephropathy \[[@R25]\], but is also obvious in other commonly prescribed agents. Another major threat to the validity of a systematic review, as to any other research endeavor, lies in conflicts of interest and study funding. It is well known that reviewers with underlying financial conflicts of interest are more likely to conclude in favor of the intervention benefiting the source of financial gains \[[@R26]\].

Whether these facts should lead to a more critical reading of their work or a comprehensive re-evaluation of their whole research project is best left at the readers' discretion, but this should also take into account the overall internal validity (e.g. blinding of patients, physicians, adjudicators, and analysts) of the work.

Conclusions {#s17}
===========

Systematic reviews and meta-analyses offer powerful methods to evaluate the clinical effects of health interventions, especially when directly applied to real world clinical practice (such as in the Best Evidence Topic \[BET\] approach) \[[@R27]\].

More collaborative efforts are however required to design, conduct and disseminate individual patient data meta-analyses in an unbiased and rigorous manner \[[@R28],[@R29]\].
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